Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Thymalin iconThymalinSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Thymalin

Beginner tier: 5 mg, daily · 1w on / 25w off · clinical trials

ImmuneResearch
~2-4 hours half-life (estimated)·Injection

Also known as: Timalin, Thymaline, THYMALIN®

A 4.1-fold mortality reduction over six to eight years. That's the headline number from Khavinson's geroprotective trials in elderly patients given biannual courses of Thymalin plus Epithalamin, a bovine thymic peptide extract containing the active dipeptides EW (L-Glu-L-Trp) and KE. The catch: all published data comes from a single Russian research group, with zero independent Western replication. Still, over 40 years of clinical use and 293 PubMed-indexed publications make Thymalin one of the most studied bioregulators in the longevity space. Adults over 60 seeking immune restoration use it in short 10-day courses, twice yearly.

What Is Thymalin?

Four amino acids changed the survival curve. In Khavinson's 6 to 8 year follow-up of elderly patients (n approximately 100)[1], biannual courses of Thymalin plus Epithalamin reduced mortality by 4.1 times compared to controls. Thymalin (also written as Timalin) is a peptide complex isolated from calf thymus gland, first registered in Russia in 1982 under Samson-Med (reg. cert. LS-000267). Its primary bioactive component, the dipeptide L-Glu-L-Trp, was later synthesized as the standalone drug Thymogen.

The mechanism is epigenetic rather than pharmacological in the traditional sense. Short peptides (EW, KE, EDP) bind to double-stranded DNA and histone proteins, triggering gene expression changes in thymic progenitor cells. T-cell precursor differentiation accelerates; CD28 expression increased roughly 6.8 times in one published study (PMC7686446). The biological effect persists for months after a single 10-day course.

Real-world use centers on adults over 60 with measurable immunosenescence. A 2021 randomized controlled trial in 80 elderly COVID-19 patients (PMC8654498) found 10 mg intramuscular daily for 10 days cut hospital mortality roughly in half (19.4% vs 40.9%). All of this originates from one research group at the St. Petersburg Institute of Bioregulation and Gerontology. No independent Western trial has attempted to replicate the findings. The data is promising and internally consistent, but the single-source limitation is real.

How Thymalin Works

Thymalin works at the gene expression level rather than through classical receptor binding. Its short dipeptides, primarily L-Glu-L-Trp (EW) and L-Lys-L-Glu (KE), interact directly with double-stranded DNA and histone proteins. This triggers epigenetic changes in thymic progenitor cell populations within 24 to 48 hours of the first dose.

The downstream effects cascade through multiple immune pathways. T-cell precursor differentiation accelerates from bone marrow-derived progenitors into mature T-lymphocytes. CD4/CD8 ratios normalize toward the healthy adult range of 1.5 to 2.5. Natural killer cell cytotoxicity increases measurably. Intracellular cyclic nucleotide levels shift, modulating immune cell signaling. Neutrophil chemotaxis and phagocytosis both improve.

Cytokine regulation is part of the picture too. Thymalin modulates IL-2 and interferon production to restore balanced immune responses rather than simply driving stimulation in one direction. This distinguishes it from single-target immunostimulants; the effect is restorative rather than purely activating.

The biological timeline matters. Because the peptide's action is epigenetic, its effects outlast plasma clearance by weeks to months. The half-life of the peptide complex itself is estimated at 2 to 4 hours. The gene expression changes it initiates persist through cell division cycles. This is why 10 days of dosing produces months of measurable immune improvement, and why continuous dosing adds nothing once the epigenetic program is running.

Thymalin Benefits

  • Thymalin benefits center on measurable immune restoration and longevity outcomes rather than subjective effects.
  • Mortality reduction of 4.1 times in Khavinson's biannual course study over 6 to 8 years (n approximately 100 elderly patients)[1]. No other peptide in the longevity space has human mortality outcome data of this duration.
  • T-cell count restoration and CD4/CD8 ratio normalization confirmed in multiple clinical cohorts. Measurable improvement appears 4 to 6 weeks after a single 10-day course.
  • Hospital mortality cut roughly in half in elderly COVID-19 patients receiving 10 mg daily for 10 days (PMC8654498, n=80; 19.4% vs 40.9% standard care).
  • NK cell cytotoxicity increases. CD28 expression rose approximately 6.8 times in one study (PMC7686446), indicating restored T-cell co-stimulatory capacity.
  • Short treatment window with long-lasting effect. Ten days of dosing produces 6 months of sustained immune marker improvement. Cost per course runs $50 to $140 for US research-grade product.
  • Exceptional safety record across 40+ years of clinical use. No serious adverse events documented in the published literature. Practically non-toxic at standard doses.

Thymalin: Science vs Community Consensus

Aligned
Scientific Evidence
Moderate
Based on 11 key studies·Research only

Short-course IM dosing (5–10 mg/day × 10 days, biannual) restores T-cell counts, CD4/CD8 ratios, and NK activity in elderly and immunocompromised patients.

Dosing studied: 5–10 mg IM daily for 5–10 days; max label dose 20 mg/day
Read the evidence (key study, limitations)

Long-term geroprotective data shows 4.1× mortality reduction (Khavinson, n=~100, 6–8 yr follow-up). COVID-19 RCT: 10 mg × 10 days reduced hospital mortality ~50% in elderly patients (19.4% vs 40.9%). All data originates from one Russian research group with no independent replication.

Key Study

PMC8654498 (2021 COVID-19 RCT, n=80) + PMID 14523363 (6–8 yr mortality, n=~100)

Limitations

Single research group (Khavinson Institute). No independent Western RCT. All studies elderly population. No formal PK characterization.

Community Experience
Moderate
4.0/5
Based on sparse English-language community

Widely trusted for immune restoration and longevity.

Community dosing: 5–10 mg IM or SC daily × 10 days, every 6–12 months
Read the reports (what users report 5, common issues 4)

Valued for short course requirement and clean safety record. Low enthusiasm for subjective effects: benefits are lab-measurable, not acutely felt.

What users report (5)
  • Immune restoration measurable at lab level after one course
  • Short 10-day course with months of lasting effect
  • Human mortality outcome data unique among longevity peptides
  • Exceptional safety: no serious adverse events across decades of clinical use
  • Low per-dose cost with EU-sourced authentic product
Common issues (4)
  • No subjective "feel": benefits require labs to confirm
  • Authenticity friction: authentic Samson-Med product from EU; US synthesized versions may differ in composition
  • Restlessness/akathisia reported by some users when stacking Thymalin + Epitalon concurrently (mechanism unclear)
  • IM vs SC debate: Russian label specifies IM only; community widely uses SC without published bioavailability data
Science & Community Aligned

Clinical protocols (5–10 mg × 10 days, biannual) and community protocols are nearly identical. Community added SC as a route option not sanctioned by the Russian label. Dose range, cycling pattern, and goals are consistent.

Thymalin Dosage Guide

Clinical TrialKhavinson Institute clinical trials (PMID 14523363)
LevelDose / InjectionFrequency
Beginner5 mg
DailyTrack
Moderate10 mg
DailyTrack
Aggressive20 mg
DailyTrack
Note:

Standard protocol: 5 to 10 mg intramuscular or subcutaneous, once daily for 10 days. Repeat every 6 months if you're over 60, or every 12 months if younger.

Reconstitution math for a 10 mg vial: add 1 mL bacteriostatic water. Each 0.1 mL (10 units on a U-100 insulin syringe) then equals 1 mg. For the beginner 5 mg dose, draw 50 units. For the standard 10 mg dose, you'll use the entire vial in one shot at 100 units; that means one vial per day for a 10-day course (10 vials total).

The thing most beginners miss: you won't feel anything. Thymalin's benefits are lab-measurable, not subjectively perceptible. Get a CBC with differential and CD4/CD8 ratio before your course and again 4 to 6 weeks after. That's how you confirm it's working.

The Russian label specifies intramuscular only. Community widely uses subcutaneous without issue, but no published bioavailability comparison exists for the extract form. If you want to match the clinical evidence exactly, go IM in the gluteal or deltoid.

Cycling Protocol

On Period
1 weeks
Off Period
25 weeks

Bioregulator protocol: 5-10 day course repeated every 6 months. Effects persist well beyond the treatment window. Some protocols call for annual courses in younger adults and biannual courses in those over 60.

Calculate your Thymalin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Thymalin Protocols by Goal

beginnerClinical Trial10 days on; repeat every 12 months (under 60) or 6 months (over 60)
Treatment Course
Wk ~1.5 (10 days)
5 mg · Once daily · Intramuscular

Expected: Improved T-cell counts and CD4/CD8 ratio within 2–4 weeks post-course. Reduced infection frequency over the following 6-month window.

Monitor: CBC with differential and CD4/CD8 ratio at baseline and 4–6 weeks post-course.

How to Use Thymalin

  1. 1
    Step 1

    Gather supplies: Thymalin 10 mg lyophilized vial, bacteriostatic water, a mixing syringe (25G 1 inch), and an injection syringe (27G or 29G, 0.5 inch for SC or 1 inch for IM). Alcohol swabs for vial tops and injection site.

  2. 2
    Step 2

    Reconstitute by adding 1 mL (100 units) of bacteriostatic water to the vial. Aim the stream against the glass wall, not directly onto the powder. Swirl gently until dissolved. Do not shake.

  3. 3
    Draw your dose

    At 1 mL per 10 mg vial: 50 units on a U-100 insulin syringe equals 5 mg (beginner). 100 units equals 10 mg (standard). For 20 mg, you'll need two vials.

  4. 4
    Inject once daily at the same time each day

    For intramuscular (label-approved route): gluteal or deltoid, 1 inch needle, slow steady push. For subcutaneous (community route): abdomen or thigh, pinch skin, 45-degree angle.

  5. 5
    Step 5

    Rotate injection sites each day across the 10-day course.

  6. 6
    Step 6

    After reconstitution, store the vial at 2 to 8 degrees C (refrigerator). Use within 10 days. Lyophilized powder stores at room temperature for up to 6 months or refrigerated for up to 3 years.

  7. 7
    Complete the full 10-day course

    Do not extend beyond 10 days; the epigenetic effects continue developing after you stop.

Alternative Routes

Intramuscular (IM)

Standard doses apply: 5–10 mg per injection

Russian label explicitly states IM route. IV explicitly prohibited per Russian prescribing information. Gluteal or deltoid site preferred.

Subcutaneous (SC)

Community uses same doses (5–10 mg); no published bioavailability comparison to IM for the extract form

Russian label does not sanction SC for Thymalin. Widely used by community for convenience. No published bioavailability or efficacy equivalence data for SC route with the bovine extract form. Cannot confirm equivalent clinical outcome.

Mixing your own vial? Use the Thymalin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Thymalin Stacking Protocols

Estimated Cost

Brand Price
Samson-Med THYMALIN® (EU pharmacy): 10 vials × 10 mg ~€59 (~$64 USD) = ~$6.40 per 10 mg dose
Generic / Research
US research-grade (synthesized): 100 mg ~$49.99–$138.95 (~$0.50–$1.39/mg); 25 mg ~$45–$80. Full 10-day course at 10 mg/day = ~$50–$140 USD.

Pricing updated 2026-04-09

Thymalin Side Effects

The most important safety concern with Thymalin isn't a side effect from the peptide itself. It's the risk of using it when you shouldn't. In anyone with an active autoimmune condition (rheumatoid arthritis, lupus, Hashimoto's thyroiditis, multiple sclerosis), Thymalin's broad T-cell stimulation can worsen flares. The Russian clinical literature studied healthy elderly patients and post-surgical recovery cases. Not established autoimmune disease.

Organ transplant recipients on immunosuppressants face a specific danger. Thymalin directly counteracts tacrolimus, cyclosporine, and mycophenolate. Using it risks organ rejection. This combination is explicitly listed in Russian prescribing information as contraindicated.

For people without autoimmune conditions or transplant history, the safety profile is remarkably clean. Across decades of clinical use and published studies, serious adverse events are absent from the literature. Injection site soreness is the most common complaint; it's mild and resolves on its own. Rare low-grade fever has been reported in a small number of patients, typically during the first few days of a course.

One community-reported issue deserves attention. Some users stacking Thymalin with Epitalon concurrently have reported restlessness or akathisia. This isn't documented in clinical studies, but the reports are consistent enough to note. Separating the two courses by 1 to 2 weeks resolves it.

Sourcing adds a layer of risk that traditional side effect profiles don't capture. Authentic Thymalin is a complex bovine extract containing multiple short peptides. US-synthesized products labeled "Thymalin" may contain only a single synthetic peptide. No published comparative analysis of US versus Russian product equivalence exists. Only a certificate of analysis confirming L-Glu-L-Trp content shows what a US product contains.

Pregnancy and breastfeeding are absolute contraindications. Known hypersensitivity to bovine-derived products or thymic peptides is another. Stop immediately and consult a physician if you develop signs of allergic reaction, unexpected immune activation, or symptoms suggesting autoimmune flare.

Common Issues & Solutions

No subjective effect after course: Expected: Thymalin benefits are immune-marker measurable, not acutely felt. Confirm response with CBC and CD4/CD8 ratio 4–6 weeks post-course.

Restlessness or akathisia during Epitalon co-administration: Anecdotally reported; not in clinical literature. Separate the two courses by 1–2 weeks if this occurs; reintroduce one at a time.

Injection site discomfort: Rotate injection sites each dose. IM gluteal/deltoid is the labeled route: ensure correct injection depth and technique.

Sourcing uncertainty (US synthetic vs EU extract): Authentic Thymalin is a bovine thymic extract with a complex dipeptide mixture. US-synthesized "Thymalin" products may differ. Only a CoA confirming L-Glu-L-Trp (EW dipeptide) content shows what the vial holds.

Repeating courses too soon: Minimum 3–4 months between courses; 6 months is standard. Effects continue to develop post-course: re-dosing before the off period ends wastes product and lacks clinical basis.

Ask AI about this page

Ask AI for a second opinion on Thymalin dosing and side effects

Contraindications

  • Pregnancy or breastfeeding
  • Known hypersensitivity to thymic peptides or bovine-derived products
  • Active autoimmune conditions requiring immunosuppressive therapy
  • Organ transplant recipients on anti-rejection medications
  • Severe allergic reactions to animal-derived biological products
  • Active malignancy with T-cell involvement (T-cell lymphoma, adult T-cell leukemia)

Drug Interactions

  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate): Thymalin may counteract immunosuppressive effects
  • Other thymic peptides (Thymosin Alpha 1, Thymogen, T-activin): overlapping mechanisms; avoid concurrent use without medical guidance
  • Corticosteroids: high-dose steroids may blunt immunostimulatory effects of Thymalin
  • Vaccines: timing may need adjustment; Thymalin could alter immune response to vaccination
  • High-dose steroid protocols blunt Thymalin's immunostimulatory mechanism, reducing or eliminating efficacy.

Product Quality

Recommended Monitoring

TestWhenTarget
CBC with differentialBaseline before course; 4–6 weeks post-courseLymphocyte count increase; normalization of pre-course lymphopenia if present
CD4/CD8 T-cell ratioBaseline; 4–6 weeks post-courseNormal adult range 1.5–2.5; improvement from depressed baseline expected
NK cell activityOptional: baseline and 4–8 weeks post-courseNot listed
CRP and IL-6If course is for acute immune recovery; baseline and post-courseNot listed
CBC with differential

Quantifies lymphocyte counts and overall immune cell populations; primary measure of Thymalin response in clinical studies

CD4/CD8 T-cell ratio

Direct marker of T-cell differentiation response; used as primary endpoint in Khavinson clinical studies

NK cell activity

Thymalin specifically enhances NK cell cytotoxicity in clinical studies; measurable via NK cytotoxicity assay

CRP and IL-6

Khavinson COVID-19 studies showed faster normalization of inflammatory markers with Thymalin vs. standard care

Thymalin Before and After

Days 1-3

Treatment initiation. No noticeable changes yet. Peptide begins modulating gene expression in immune cells and thymic tissue.

Days 4-7

Early immune markers begin shifting. Some patients report improved energy or reduced frequency of minor symptoms. T-cell precursor differentiation accelerates.

Days 8-10

Course completion. Measurable improvements in T-cell counts and CD4/CD8 ratios in clinical studies. NK cell activity increases.

Weeks 2-8
post-course

Immune improvements continue to develop after the course ends. Reduced incidence of acute respiratory infections observed in clinical cohorts. Immune markers stabilize at improved levels.

Months 3-6
maintenance

Sustained immune benefits from a single course. Khavinson studies showed reduced infection rates and improved survival persisting for 6+ months. Next course typically administered at the 6-month mark.

What to Expect

Days 1 through 3, Course Initiation: The dipeptides EW and KE start binding to DNA and histone proteins almost immediately. Epigenetic changes in thymic progenitor cell gene expression begin within 24 to 48 hours. You won't notice anything. Some users report slight fatigue or a mild energy shift around day 2 or 3. Injection site soreness is possible; rare low-grade fever has been reported.

Days 4 through 10, Active Course: T-cell precursor differentiation picks up speed. CD28 expression increases roughly 6.8 times based on published data (PMC7686446). NK cell activity starts climbing. Most people still report zero perceptible change, which is normal. A minority notice improved energy or fewer minor symptoms. Injection site reactions may continue; no systemic adverse effects have been documented in clinical studies.

Weeks 2 through 4 Post-Course, Immune Consolidation: This is when labs start telling the story. T-cell counts and CD4/CD8 ratios show measurable improvement in clinical study data. NK cell activity peaks. The biological effect outlasts the peptide's plasma presence by weeks. Some users note fewer minor infections. There's still no acute subjective "feel" to this peptide.

Months 2 through 6, Sustained Benefit Window: Khavinson's studies showed reduced infection rates and improved immune markers persisting for a full 6 months after a single 10-day course. The mortality reduction data (4.1 times) came from biannual courses sustained over 6 to 8 years. Community consensus aligns: fewer colds, faster recovery from illness. The value proposition is lab numbers and longevity rationale, not day-to-day perceptible changes. Next course is typically scheduled at the 6-month mark for adults over 60.

Detailed Timeline: Science vs Community

Days 1–3
Science

Dipeptides (EW, KE) bind to DNA/histone proteins; epigenetic changes in thymic progenitor cell gene expression begin within 24–48 hours.

Community

No noticeable changes. Some users report slight fatigue or a mild energy shift on days 2–3.

Days 4–10
Science

T-cell precursor differentiation accelerates; CD28 expression increases ~6.8× (PMC7686446). NK cell activity begins rising.

Community

Majority report no perceptible change. A minority note improved energy or slight reduction in minor symptoms.

Weeks 2–4 (post-course)
Science

T-cell counts and CD4/CD8 ratio measurably improved in clinical studies. NK activity peaks. Biological effect outlasts peptide plasma presence by weeks.

Community

Labs begin showing improvement. Some users note reduced incidence of minor infections. No acute subjective "feel."

Months 2–6 (maintenance window)
Science

Khavinson studies show reduced infection rates and improved immune markers persisting for 6 months post-single-course. Mortality reduction data based on biannual courses over 6–8 years.

Community

Community consensus: fewer colds, faster recovery from illness. Valued primarily for labs and longevity rationale rather than acute subjective experience.

Pharmacokinetics

Half-Life
3h
Bioavailability
IM/SC: not formally characterized
Tmax
~30-60 minutes (estimated)
Data Confidence
low

Source: Estimated from dipeptide/short peptide pharmacokinetics; no formal PK study published for Thymalin complex

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours (estimated)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Thymalin

  • Adults over 60 with age-related immune decline (immunosenescence)
  • Individuals with chronic or recurrent infections
  • Post-surgical or post-illness immune recovery
  • Those seeking periodic immune system maintenance
  • Patients with reduced T-cell counts or impaired CD4/CD8 ratios

Related Peptides

What Changed for Thymalin

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations

References

  1. [1]Peptides of Pineal Gland and Thymus Prolong Human Life (Neuroendocrinol Lett 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 6 months, refrigerated up to 3 years
After Reconstitution
Refrigerate at 2-8°C, use within 10 days
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

Different levels of the immune system. Thymalin is a bovine thymic extract containing multiple short peptides (EW, KE, EDP) that work epigenetically at the thymic stem cell level, promoting T-cell precursor differentiation. Thymosin Alpha-1 is a single synthetic 28-amino-acid peptide that works downstream on mature immune cells via TLR signaling. Sequential use (Thymalin course, then TA1 maintenance) is logical; concurrent use is commonly done though not formally studied.

Thymalin works through epigenetic regulation: its dipeptides trigger lasting changes in gene expression in thymic progenitor and T-cell populations. The biological effect outlasts the peptide's presence by weeks. Continuous dosing isn't just unnecessary; it may be counterproductive since the thymus needs time to consolidate the changes. The 6-month off period allows full expression before the next course.

This is the highest-risk scenario. Thymalin upregulates T-cell numbers and activity across the board. In RA, lupus, Hashimoto's, or MS where the immune system is already attacking self-antigens, broad T-cell stimulation risks worsening flares. The Russian clinical literature studied healthy elderly and post-surgical recovery cases, not established autoimmune disease. Don't use during active flare. Require specialist oversight for any autoimmune background.

It comes from Khavinson's geroprotective study: elderly patients (primarily women, 66-89 years old) followed for 6-8 years with biannual courses of Thymalin + Epithalamin. The treated group had 4.1x lower mortality than controls (PMIDs 14523363, 12577695). The caveats are real: single research group, single Russian center, elderly population only, no independent Western replication. Compelling data, but not replicated.

Published clinical evidence exists. A 2021 RCT (PMC8654498, n=80 elderly patients) found Thymalin 10 mg IM daily for 10 days reduced hospital mortality by roughly 50% (19.4% vs 40.9%) versus standard care. A 2022 follow-up (PMID 36169363) found it outperformed tocilizumab for coagulation marker normalization. Same caveats as always: single Russian group, small samples, no independent replication.